A Deworming Drug Is Showing Up in Cancer Research. Scientists Can No Longer Ignore It.

In 2016, a man named Joe Tippens was given three months to live. Small-cell lung cancer. Terminal. He was enrolled in a clinical trial for an immunotherapy drug, but his doctors had no real expectation it would save him.

What happened next became one of the most discussed — and most dismissed — stories in alternative medicine. Tippens began taking fenbendazole. A deworming drug used in veterinary medicine. Cost: a few dollars per dose. Available at agricultural supply stores.

Three months later, a PET scan showed no detectable cancer cells anywhere in his body.

He was the only patient among 1,100 enrolled in that clinical trial to achieve complete remission.

The Establishment Response

When the Tippens story went viral — first in South Korea, then globally — the medical establishment responded predictably. Anecdotal. Uncontrolled. Correlation, not causation. He was on immunotherapy. We cannot attribute his remission to fenbendazole.

All of this is technically true.

What is also true is that the story triggered a wave of scientific interest that has now produced over 50 peer-reviewed publications examining fenbendazole's mechanism of action against cancer cells. Researchers are not dismissing it. They are studying it with increasing urgency. And what they are finding is genuinely interesting.

What the Research Is Actually Showing

How Cancer Cells Generate Energy — and How Fenbendazole Disrupts It

Normal cells generate energy primarily through aerobic respiration — oxygen-dependent metabolism in the mitochondria. Cancer cells are different. Most cancer cells rely heavily on glycolysis — a less efficient but faster process of metabolising glucose even in the presence of oxygen. This is called the Warburg Effect, and it is one of cancer's defining biological signatures.

Fenbendazole inhibits glucose uptake and disrupts glycolytic pathways in cancer cells. Put simply: it may starve cancer cells of their preferred fuel source while leaving normal cells — which are less reliant on glycolysis — relatively unaffected.

Microtubule Disruption

Fenbendazole's primary mechanism as an antiparasitic is binding to beta-tubulin — disrupting the microtubule structures parasites need to survive. This is also how several established chemotherapy drugs work (vincristine, paclitaxel). Researchers have found that fenbendazole binds to cancer cell beta-tubulin with similar disruptive effect, inducing cell cycle arrest and triggering apoptosis — programmed cell death.

The Cervical Cancer Data

A 2025 study published in Molecules examined fenbendazole against both cervical cancer cells and cervical cancer stem cells — the particular subpopulation that drives therapy resistance and recurrence. Results showed dose-dependent growth inhibition in both cell types, with the cancer stem cells — normally the hardest to eliminate — showing significant apoptosis.

The Case Series

A 2025 publication in Case Reports in Oncology documented three patients with advanced cancers — metastatic breast cancer, metastatic prostate cancer, and melanoma — who self-administered fenbendazole alongside standard therapies. All three showed marked responses. One patient with metastatic breast cancer achieved what clinicians described as complete remission.

The paper was subsequently complicated by a retraction notice related to disclosure requirements — not to the clinical data itself. The authors and the cases remain part of the published record.

Why Is This Not in Clinical Trials Yet?

This is the question that researchers themselves are asking loudly.

Fenbendazole is cheap. Generically available. Cannot be patented. There is no pharmaceutical incentive to fund a billion-dollar clinical trial for a drug that any company can manufacture and sell without exclusivity protection.

"Given the low cost of fenbendazole, its high safety profile, accessibility, and unique anti-proliferative activities, fenbendazole would be the preferred benzimidazole compound to treat cancer. Clinical trials should be funded and performed."

The FDA has fast-tracked oxfendazole — a fenbendazole metabolite — for a separate parasitic indication, meaning the compound family is not without regulatory interest. But human oncology trials specifically examining fenbendazole remain absent from the clinical trial registries. The scientific rationale exists. The funding incentive does not.

What Fenbendazole Actually Helps With Right Now

To be unambiguous: fenbendazole is not a proven cancer treatment. No responsible source should claim otherwise. The published research is in vitro and animal studies, with case reports. Human clinical data does not yet exist.

What fenbendazole does do, with decades of safety data behind it, is eliminate intestinal parasites — comprehensively, safely, and cheaply.

And this matters more than most Kenyans realise. The WHO estimates over 1.5 billion people globally carry soil-transmitted parasitic infections. In East Africa, the prevalence is among the highest in the world. Parasitic loads are associated with chronic nutrient depletion, gut inflammation, impaired immunity, and — increasingly — with resistance to standard medical treatments for unrelated conditions.

Treating a confirmed or suspected parasitic load is not fringe medicine. It is basic preventive health. In Kenya it is also significantly under-addressed.

Following This Research Yourself

The primary sources are all publicly accessible:

• ›PubMed search: "fenbendazole anticancer" — 50+ papers
• ›Anticancer Research, Vol. 44, September 2024 — Nguyen et al.
• ›Frontiers in Pharmacology, 2025 — Pan et al.
• ›Molecules, Vol. 30, 2025 — Lei et al.
• ›Case Reports in Oncology, 2025 — three-patient case series

The research is real. The mechanism is scientifically coherent. The clinical data gap is a function of economics, not biology. Draw your own conclusions.

For educational purposes only. AltCure is a dietary supplement, not a medicine or cancer treatment. Consult your physician before taking any supplement, especially if you have underlying health conditions. The studies referenced are in vitro and animal studies with case reports; human clinical trial data for fenbendazole as a cancer treatment does not currently exist.